Akebia Therapeutics (AKBA) Intangibles (2018 - 2024)

Akebia Therapeutics (AKBA) has 7 years of Intangibles data on file, last reported at $9.0 million in Q3 2024.

• Intangibles for Q3 2024 came in at $9.0 million, down 80.0% year-over-year; the trailing twelve-month figure through Sep 2024 was $9.0 million (down 80.0% YoY), and the FY2023 annual result was $36.0 million, down 50.0% from the prior year.
• Intangibles fell to $9.0 million in Q3 2024 per AKBA's latest filing, from $18.0 million in the prior quarter.
• Over five years, Intangibles peaked at $282.1 million in Q1 2020 and troughed at $9.0 million in Q3 2024.
• A 5-year average of $95.6 million and a median of $90.1 million in 2022 frame the typical range for Intangibles.
• The sharpest annual moves came in 2020 and 2024: Intangibles declined 11.43% in 2020, then slumped 80.0% in 2024.
• A 5-year view of Intangibles shows it stood at $144.2 million in 2020, then slipped by 25.0% to $108.1 million in 2021, then sank by 33.33% to $72.1 million in 2022, then sank by 50.0% to $36.0 million in 2023, then plunged by 75.0% to $9.0 million in 2024.
• Business Quant data shows AKBA's Intangibles at $9.0 million in Q3 2024, $18.0 million in Q2 2024, and $27.0 million in Q1 2024.